Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5766581

Title:Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
Inventors:Bartley, Timothy D.; Thousand Oaks, CA, USA
Bogenberger, Jakob M.; Camarillo, CA, USA
Bosselman, Robert A.; Thousand Oaks, CA, USA
Hunt, Pamela; Thousand Oaks, CA, USA
Kinstler, Olaf B.; Thousand Oaks, CA, USA
Samal, Babru B.; Moorpark, CA, USA
Summary:This invention discloses mammalian treatment methods involving proteins referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately resulting in the production of platelets. Also disclosed are MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol. Methods of preparation and treatment are emphasized. This invention is an expansion of number US5795569, in which the novel properties of MGDFs were introduced.
Abstract:Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. The MGDF proteins and derivatives are useful in methods for treating mammals to increase platelets and/or megakaryocytes. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5766581
Application Number:US1995000413803
Date Filed:30/03/1995
Date Published:16/06/1998
Assignee:Amgen Inc., Thousand Oaks, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021